An Effective Non-Invasive Solution for Nasal Drug Delivery

18th April 2019: Nasal drug delivery is mainly used as a treatment of local infection in the paranasal sinuses and nasal courses such as non-allergic and allergic rhinitis and sinusitis. This technique is mainly used to ease the problem of gradual absorption of drugs, degeneration before reaching the focus place, and poor bioavailability. Furthermore, it supports in resolving problems associated with the gastrointestinal (GI) tract and first-pass metabolism in the liver.

High Demand for Generic Forms of Spray Drugs to Boost Spray Dosage Form

The major dosage form-variants of nasal drug delivery technology are a drop, nasal spray, powder, and gel. The sprays segment surpassed the market due to the allergic rhinitis, increasing demand for common forms of spray drugs, and increasing incidences of infections. 

In 2016, as per the Healthy People 2020, made available by Office of Disease Prevention and Health Promotion, morbidity exists and differences in asthma mortality, particularly in middle-class populations and minority, causes people to tend more toward profitable choices.

In addition, Nasal sprays are followed by nasal drop segment and is anticipated to be the highest growing dosage form sector over the forthcoming period owing to product success rate for this treatment and affordability. 

Moreover, increasing patient compliance and inclination toward self-administration are likely to increase the growth of this segment. Furthermore, the accessibility of several numbers of drops in the market is anticipated to contribute to the nasal drop growth in the future. 

Market Insights

The market is expected to face strong competition throughout the forthcoming period due to the existence of multinational establishments. Novel product development, joint ventures, and geographical expansion are some of the important policies accepted by significant market key players. 

For example, Opti Nose, Inc., in 2016, declared a pipeline scheme to monitor nose-to-brain application, which is sponsored by Research Council of Norway for curing narcolepsy of Orexin-A using Opti Nose Bi-Directional Breath Powered delivery technology.

North America will observe robust development over the forecast period owing to established economies in the region and consumer consciousness about nasal products.

Leading players operating in the nasal drug delivery technology market include AstraZeneca PLC; GlaxoSmithKline PLC; B.F. Ascher & Company, Inc.; Becton, Dickinson and Company; Pfizer, Inc.; Opti Nose, Inc.; Cadila Pharmaceuticals Ltd.; Douglas Pharmaceuticals Ltd.; Promius Pharma, LLC; PendoPharm, Inc.; NAVEH Pharma Ltd and ENT Technologies Pty. Ltd.